Subgroup analysis demonstrated that second‐line combination immunotherapy significantly improved response and survival rates compared to PD‐1 inhibitor monotherapy in immunotherapy‐naive ESCC patients. Here, PDCD1 is linked to esophageal squamous cell carcinoma.